Icagen (ICGN) Senicapoc Fails In Phase IIa Study

October 26, 2009 4:37 PM EDT

Icagen, Inc. (Nasdaq: ICGN) reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.

In this double blind placebo-controlled study, 69 patients were randomized to receive either senicapoc at a maintenance dose of 40 mg/day or placebo. All subjects were tested for pulmonary function following a standardized treadmill exercise regimen at baseline, two and four weeks after treatment. The results of the pulmonary function tests were compared between the treatment groups, adjusting for differences in baseline values.

Although the Company will continue to evaluate the data from this trial, it does not anticipate continuing clinical development of senicapoc at this time.

Related Categories

FDA
Hot List

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?